Autoimmunity risk alleles: Hotspots in B cell regulatory signaling pathways

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 1928-1931

  Cambier, John C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD72 ANTIGEN; CD79A ANTIGEN; CD79B ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; FC RECEPTOR IIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR 22; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACHILLES TENDON; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; FEEDBACK SYSTEM; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; MALE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22;

EID: 84877157906     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69289     Document Type: Review

References (27)

1. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol. 2007;95:83-110.
2. Cruickshank MN, et al. Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21). Mol Immunol. 2012;52(3-4):165-173.
3. Kono H, et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005;14(19):2881-2892.
4. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med. 2001;49(2):157-165.
5. Manjarrez-Orduno N, et al. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet. 2012;44(11):1227-1230.
6. Taylor KE, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011;7(2):e1001311.
7. Dai X, et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest. 2013;123(5):2024-2036.
8. Bottini N, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36(4):337-338.
9. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol. 2006;18(4):207-213.
10. Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity. Autoimmunity. 2007;40(8):582-590.
11. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol. 2008;26:29-55.
12. Vang T, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37(12):1317-1319.
13. Zhang J, et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet. 2011;43(9):902-907.
14. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol. 2007;7(8):633-643.
15. Pelanda R, Torres RM. Receptor editing for better or for worse. Curr Opin Immunol. 2006;18(2):184-190.
16. Pelanda R, Torres RM. Central B-cell tolerance: where selection begins. Cold Spring Harb Perspect Biol. 2012;4(4):a007146.
17. Horikawa K, Nishizumi H, Umemori H, Aizawa S, Takatsu K, Yamamoto T. Distinctive roles of Fyn and Lyn in IgD- and IgM-mediated signaling. Int Immunol. 1999;11(9):1441-1449.
18. DeFranco AL, Chan VW, Lowell CA. Positive and negative roles of the tyrosine kinase Lyn in B cell function. Semin Immunol. 1998;10(4):299-307.
19. Castillejo-Lopez C, et al. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis. 2012;71(1):136-142.
20. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290(5489):84-89.
21. Pao LI, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity. 2007;27(1):35-48.
22. O'Neill SK, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity. 2011;35(5):746-756.
23. Landego I, et al. Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates B-cell activation and autoantibody production. Eur J Immunol. 2012;42(10):2760-2770.
24. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283-296.
25. Browne CD, Del Nagro CJ, Cato MH, Dengler HS, Rickert RC. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity. 2009;31(5):749-760.
26. Yokoyama K, et al. BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor. EMBO J. 2002;21(1-2):83-92.
27. Fujimoto M, et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity. 2000; 13(1):47-57.